{"id":"NCT01202188","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2012-02","completion":"2012-03","firstPosted":"2010-09-15","resultsPosted":"2013-05-03","lastUpdate":"2013-09-09"},"enrollment":2144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"indacaterol and glycopyrronium (QVA149)","otherNames":[]},{"type":"DRUG","name":"glycopyrronium (NVA237)","otherNames":[]},{"type":"DRUG","name":"indacaterol (QAB149)","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"indacaterol and glycopyrronium (QVA149)","type":"EXPERIMENTAL"},{"label":"glycopyrronium (NVA237)","type":"ACTIVE_COMPARATOR"},{"label":"indacaterol (QAB149)","type":"ACTIVE_COMPARATOR"},{"label":"tiotropium","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.","primaryOutcome":{"measure":"Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment","timeFrame":"23 hours 15 minutes and 23 hour 45 minute post-dose Week 26","effectByArm":[{"arm":"Indacaterol and Glycopyrronium (QVA149)","deltaMin":1.45,"sd":0.01},{"arm":"Indacaterol (QAB149)","deltaMin":1.38,"sd":0.01},{"arm":"Glycopyrronium (NVA237)","deltaMin":1.36,"sd":0.01}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":166,"countries":["United States","Australia","Bulgaria","Canada","France","Germany","Guatemala","Hungary","Japan","Philippines","Poland","Russia","Slovakia","South Africa","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["25609942"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":474},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Cough","Upper respiratory tract infection","Upper respiratory tract infection bacterial"]}}